BISAMIDATE PHOSPHONATE COMPOUNDS AS INHIBITORS OF FRUCTOSE 1,6-BISPHOSPHATASE Russian patent published in 2006 - IPC C07F9/655 C07F9/44 C07F9/6561 C07F9/6558 A61K31/664 A61P3/10 

Abstract RU 2273642 C2

FIELD: chemistry of organophosphorus compounds, biochemistry, medicine, pharmacy.

SUBSTANCE: invention relates to new bisamidate phosphonate compounds that are inhibitors of fructose 1,6-bis-phosphatase. Invention describes a compound of the formula (IA): wherein compound of the formula (IA) is converted in vivo or in vitro to compound of the formula M-PO3H2 that is inhibitor of fructose 1,6-bis-phosphatase and wherein M represents R5-X- wherein R5 is chosen from a group consisting of compounds of the formula or wherein each G is chosen from the group consisting of atoms C, N, O, S and Se and wherein only one G can mean atom O, S or Se and at most one G represents atom N; each G' is chosen independently from the group consisting of atoms C and N and wherein two G' groups, not above, represent atom N; A is chosen from the group consisting of -H, -NR42, -CONR42, -CO2R3, halide, -S(O)R3, -SO2R3, alkyl, alkenyl, alkynyl, perhaloidalkyl, haloidalkyl, aryl, -CH2OH, -CH2NR42, -CH2CN, -CN, -C(S)NH2, -OR2, -SR2, -N3, -NHC(S)NR42, -NHAc, or absent; each B and D is chosen independently from the group consisting of -H, alkyl, alkenyl, alkynyl, aryl, alicyclyl, aralkyl, alkoxyalkyl, -C(O)R11, -C(O)SR11, -SO2R11, -S(O)R3, -CN, -NR92, -OR3, -SR3, perhaloidalkyl, halide, -NO2, or absent and all groups except for -H, -CN, perhaloidalkyl, -NO2 and halide are substituted optionally; E is chosen from the group consisting of -H, alkyl, alkenyl, alkynyl, aryl, alicyclyl, alkoxyalkyl, -C(O)OR3, -CONR42, -CN, -NR92, -NO2, -OR3, -SR3, perhaloidalkyl, halide, or absent; all groups except for -H, -CN, perhaloidalkyl and halide are substituted optionally; J is chosen from the group consisting of -H, or absent; X represents optionally substituted binding group that binds R5 with phosphorus atom through 2-4 atoms comprising 0-1 heteroatom chosen from atoms N, O and S with exception that if X represents urea or carbamate then there are 2 heteroatoms that determine the shortest distance between R5 and phosphorus atom and wherein atom bound with phosphorus means carbon atom and wherein X is chosen from the group consisting of -alkyl(hydroxy)-, -alkynyl-, - heteroaryl-, -carbonylalkyl-, -1,1-dihaloidalkyl-, -alkoxyalkyl-, -alkyloxy-, -alkylthioalkyl-, -alkylthio-, -alkylaminocarbonyl-, -alkylcarbonylamino-, -alkoxycarbonyl-, -carbonyloxyalkyl-, -alkoxycarbonylamino- and -alkylaminocarbonylamino- and all groups are substituted optionally; under condition that X is not substituted with -COOR2, -SO3H or -PO3R22; n means a whole number from 1 to 3; R2 is taken among the group -R3 and -H; R3 is chosen from the group consisting of alkyl, aryl, alicyclyc and aralkyl; each R4 is chosen independently from the group consisting of -H and alkyl, or R4 and R4 form cycloalkyl group; each R9 is chosen independently from the group consisting of -H, alkyl, aryl, aralkyl and alicyclyl, or R9 and R9 form in common cycloalkyl group; R11 is chosen from the group consisting of alkyl, aryl, -NR22 and -OR2; each R12 and R13 is chosen independently from the group consisting of hydrogen atom (H), lower alkyl, lower aryl, lower aralkyl wherein all groups are substituted optionally, or R12 and R13 in common are bound through 2-5 atoms comprising optionally 1-2 heteroatoms chosen from the group consisting of atoms O, N and S to form cyclic group; each R14 is chosen independently from the group consisting of -OR17, -N(R17)2, -NHR17, -NR2OR19 and -SR17; R15 is chosen from the group consisting of -H, lower alkyl, lower aryl, lower aralkyl, or in common with R16 is bound through 2-6 atoms comprising optionally 1 heteroatom chosen from the group consisting of atoms O, N and S; R16 is chosen from the group consisting of -(CR12R13)n-C(O)-R14, -H, lower alkyl, lower aryl, lower aralkyl, or in common with R15 is bound through 2-6 atoms comprising optionally 1 heteroatom chosen from the group consisting of atoms O, N and S; each R17 is chosen independently from the group consisting of lower alkyl, lower aryl and lower aralkyl and all groups are substituted optionally, or R17 and R17 at atom N are bound in common through 2-6 atoms comprising optionally 1 heteroatom chosen from the group consisting of atoms O, N and S; R18 is chosen independently among the group consisting of hydrogen atom (H), lower alkyl, aryl, aralkyl, or in common with R12 is bound through 1-4 carbon atoms forming cyclic group; each R19 is chosen independently from the group consisting of -H, lower alkyl, lower aryl, lower alicyclyl, lower aralkyl and -COR3; and under condition that when G' represents nitrogen atom (N) then the corresponding A, B, D or E are absent; at least one from A and B, or A, B, D and E is chosen from the group consisting of -H, or absent; when G represents nitrogen atom (N) then the corresponding A or B is not halide or group bound directly with G through a heteroatom; and its pharmaceutically acceptable salts. Also, invention describes a method for treatment or prophylaxis of diabetes mellitus, a method for inhibition of activity 0f fructose 1,6-bis-phosphatase, a method for decreasing blood glucose in animals, a method for treatment of diseases associated with glycogen deposition, a method for inhibition of gluconeogenesis in animal and a pharmaceutical composition based on compounds of the formula (IA).

EFFECT: valuable medicinal and biochemical properties of compounds.

69 cl, 7 tbl, 64 ex

Similar patents RU2273642C2

Title Year Author Number
COMBINATED INHIBITORS OF FBP-ASE AND ANTIDIABETIC AGENTS FOR DIABETES TREATMENT 2001
  • Van Pul'E Paul' D.
  • Ehrion Mark D.
  • Fudzivara Tosikhiko
RU2328308C2
COMBINATION OF INHIBITORS OF FBP-ASE AND SENSITIZING AGENTS OF INSULIN FOR DIABETES MELLITUS TREATMENT 1999
  • Ehrion Mark D.
  • Van Pul'E Paul'
RU2227749C2
SYNTHESIS OF 3-AMINO-3-ARYLPROPANOATES 2000
  • Abdel'-Magid Akhmed F.
  • Kokhen Judit Kh.
  • Mar'Janoff Sintija A.
  • Villani Frehnk Dzhon Ml.
  • Zong Khua M.
RU2225859C2
DERIVATIVES OF PHOSPHONESUCCINIC ACID AND THEIR PHARMACOLOGICALLY ACCEPTABLE SALTS AND COMPOSITION BASED ON THEREOF 1992
  • Khristos Tsaklakidis
  • Ehlmar Bozies
  • Angelika Ehssvajn
  • Frider Bauss
RU2115656C1
METHOD OF PREPARING 3-HALOGENALKYL-1H- PYRAZOLES 1996
  • Zkhi Benksin
  • Nevaz Murad
  • Toli Dzhon Dzh.
  • Bertensho Stefen
RU2169143C2
DIKETONE AS INTERMEDIATE FOR 3-HALOGENE-1H-PYRASOLES 1996
  • Zkhi Benksin
  • Nevaz Murad
  • Toli Dzhon Dzh.
  • Bertensho Stefen
RU2251543C2
AMINO-DERIVATIVES, METHOD OF INHIBITION OF SYNTHESIS OF NITROGEN OXIDE, METHOD OF SELECTIVE INHIBITION OF SYNTHESIS OF NITROGEN OXIDE PRODUCED BY INDUCIBLE NO-SYNTHASE, METHOD OF DECREASE OF NITROGEN OXIDE LEVEL, PHARMACEUTICAL COMPOSITION 1995
  • Khollinan E.Ehnn
  • Khansen Donal'D V.
  • Tsimbalov Sofija
RU2152927C1
NEW HETEROCYCLIC COMPOUNDS AS PHARMACEUTICALS 2000
  • Ovehn Serzh
  • Shabrie De Lasson'Er P'Er-Eht'Enn
RU2260009C2
METHOD FOR OBTAINING DIFLUOROMETHYLENE COMPOUND 2019
  • Ohtsuka, Tatsuya
  • Kuroki, Yoshichika
  • Shirai, Atsushi
  • Hosokawa, Moe
  • Kishikawa, Yosuke
RU2757918C1
HYDROXYETHYLAMINOSULFONEAMIDES, INTERMEDIATE COMPOUNDS, PHARMACEUTICAL COMPOSITION, METHOD OF INHIBITION RETROVIRAL PROTEASES, METHOD OF TREATMENT OF RETROVIRAL INFECTIONS, METHOD OF TREATMENT OF AIDS 1993
  • Majkl L. Vaskes
  • Richard A. Mjuller
  • Dzhon Dzh. Tehlli
  • Dehniehl Getman
  • Gehri A. Dekreschentso
  • Dzhon N. Freskos
RU2173680C2

RU 2 273 642 C2

Authors

Tszjan Tao

Kasibkhatla Srinivas Rao

Reddi K. Radzha

Dates

2006-04-10Published

2000-12-22Filed